Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: A pilot study

作     者：Nikolaos K.Gatselis Sarah P.Georgiadou Nikolaos Tassopoulos Kalliopi Zachou Christos Liaskos Angelos Hatzakis Georgios N.Dalekos 

作者机构：Department of Internal Medicine Research Laboratory of Internal Medicine Medical SchoolUniversity of Thessaly Larissa Greece Department of Internal Medicine Western Attica HospitalAthensGreece Department of Internal Medicine Research Laboratory of Internal MedicineMedical SchoolUniversity of Thessalv Larissa.Greece Academic Liver UnitDepartment of Internal MedicineMedical SchoolUniversity of Thessaly LarissaGreece Department of Internal Medicine Research Laboratory of Internal MedicineMedical SchoolUniversity of Thessaly LarissaGreece Department of Hygiene and Epidemiology National Retrovirus Reference CenterAthens University Medical SchoolAthensGreece Department of Internal Medicine Research Laboratory of Internal MedicineMedical SchoolUniversity of Thessaly LarissaGreece Academic Liver UnitDepartment of Internal MedicineMedical SchoolUniversity of Thessaly LarissaGreece 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2005年第11卷第4期

页      面：482-487页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：HCV infection Autoantibodies Interferon-alpha 

摘      要：AIM: Various side effects have been reported in patients infected with hepatitis C virus (HCV) who were treated with interferon-alpha (IFN-α), including the appearance or exacerbation of underlying autoimmune diseases and the development of a variety of organ and non-organ specific autoantibodies (NOSA). However, very few studies in adults have been strictly designed to address: whether the prevalence and the titre of organ and NOSA in serial samples of HCV-treated patients were affected by IFN-α, and the impact of these autoantibodies on the treatment outcome of HCV patients. METHODS: We investigated whether parietal cell autoantibodies (PCA) and/or NOSA were related with treatment-outcome in 57 HCV-treated patients (19 sustained-responders, 16 relapsers, 22 non-responders). Serum samples from patients were studied blindly at three time-points (entry, end of treatment and end of followup). For the detection of autoantibodies we used indirect immunofluorescence, commercial and in-house ELISAs. RESULTS: Sustained biochemical response was associated with ANA-negativity at the entry or end of follow up. Sustained virological response was associated with the absence of PCA at the entry. Combined virological and biochemical sustained response (CVBSR) was associated with the absence of antinuclear antibodies (ANA) at the end of follow up and PCA-negativity at the entry. Sustained virological and CVBSR were associated with a reduction of ANA and SMA titers during therapy. CONCLUSION: Although PCA and/or NOSA seropositivity should not affect the decision to treat HCV patients, the presence of some of them such as ANA, PCA and SMA before treatment or their increase during therapy with IFN- a may predict a worse response, indicating the need for a closer monitoring during treatment of HCV patients positive for these autoantibodies.